Your browser doesn't support javascript.
loading
Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.
Francica, Brian J; Holtz, Anja; Lopez, Justine; Freund, David; Chen, Austin; Wang, Dingzhi; Powell, David; Kipper, Franciele; Panigrahy, Dipak; Dubois, Raymond N; Whiting, Chan C; Prasit, Peppi; Dubensky, Thomas W.
Afiliação
  • Francica BJ; Tempest Therapeutics, Brisbane, California.
  • Holtz A; Tempest Therapeutics, Brisbane, California.
  • Lopez J; Tempest Therapeutics, Brisbane, California.
  • Freund D; Tempest Therapeutics, Brisbane, California.
  • Chen A; Tempest Therapeutics, Brisbane, California.
  • Wang D; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Powell D; Tempest Therapeutics, Brisbane, California.
  • Kipper F; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Panigrahy D; Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Dubois RN; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
  • Whiting CC; Tempest Therapeutics, Brisbane, California.
  • Prasit P; Tempest Therapeutics, Brisbane, California.
  • Dubensky TW; Tempest Therapeutics, Brisbane, California.
Cancer Res Commun ; 3(8): 1486-1500, 2023 08.
Article em En | MEDLINE | ID: mdl-37559947

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prostaglandinas / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prostaglandinas / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article